多系统萎缩治疗研究进展

Progress in treatment of multiple system atrophy

多系统萎缩(MSA)是一种成年发病的进行性的神经系统变性病,可分为帕金森型(MSA-P)和小脑型(MSA-C),临床表现为快速进展的自主神经功能障碍和运动功能障碍。MSA的病因尚不清楚,多种致病因素参与MSA发病,因此除了有限的对症治疗外,尚缺乏疾病修饰疗法以阻止疾病进展。目前,靶向α突触核蛋白、神经炎症和神经营养支持的动物和临床研究正在探索中,现就最新进展进行综述,以期提高临床对MSA精准化治疗的认识。

Multiple system atrophy(MSA)is an adult-onset and progressive neurodegenerative disease,is clinically classified into two subtypes:MSA with predominant parkinsonism(MSA-P)and MSA with predominant cerebellar ataxia(MSA-C),characterized by dysautonomia and dyskinesia.The etiology of MSA is still unknown,multiple pathogenic factors are involved in the pathogenesis of this disease,therefore,in addition to limited symptomatic treatment,there is still a lack of disease modifying therapy to prevent the progress of the disease.Currently,animal and clinical studies targeting α-synuclein,neuroinflammation and neurotrophic supporting are being explored,so this article reviewed the latest progresses to improve the clinical understanding of treatment of MSA.